A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Last updated:
2026-08-22
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

ROSETTA CRC-203: A BLINDED, RANDOMIZED PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, UNRESECTABLE, OR METASTATIC COLORECTAL CANCER

Intervention/treatment:
PUMITAMIG (BMS-986545; BNT327)
Medical condition:
METASTATIC COLORECTAL CANCER
Protocol code:
CA266-0003
Control number:
303284
Status:
Recruiting
Approved:
December 12, 2025
Trial phase:
Phase 2, Phase 3
For more information:
ClinicalTrials.gov - NCT07221357
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role
CONTACT
Phone:
855-907-3286
Name
First line of the email MUST contain NCT # and Site #.
Role
CONTACT
Sponsor
BRISTOL-MYERS SQUIBB CANADA

Locations

Alberta

Local Institution - 0550
Calgary, Alberta, T2N 5G2
Not yet recruiting
Name
Site 0550
Role
CONTACT

Nova Scotia

Local Institution - 0260
Halifax, Nova Scotia, B3H 3A7
Not yet recruiting
Name
Site 0260
Role
CONTACT

Ontario

Local Institution - 0255
Ottawa, Ontario, K1H 8L6
Not yet recruiting
Name
Site 0255
Role
CONTACT
Local Institution - 0421
Toronto, Ontario, M5G 2M9
Not yet recruiting
Name
Site 0421
Role
CONTACT
Local Institution - 0424
Toronto, Ontario, M4N 3M5
WITHDRAWN
Name
Site 0424
Role
CONTACT

Quebec

Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, H2X 3E4
Recruiting
Name
Francine Aubin, Site 0258
Role
CONTACT
Phone:
5148908000
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUS
Sherbrooke, Quebec, J1H 5N4
Recruiting
Name
Frederic Lemay, Site 0261
Role
CONTACT
Phone:
819-346-1110
Jewish General Hospital
Montreal, Quebec, H3T 1E2
Recruiting
Name
Petr Kavan, Site 0423
Role
CONTACT
Phone:
5143408222ext23460
Did you find what you were looking for?